VIP (Vasoactive Intestinal Peptide): Research Overview

VIP, short for vasoactive intestinal peptide, is a 28-amino-acid neuropeptide with wide-ranging effects in the body. It appears in the gut, brain, lungs, immune cells, and other tissues. Research links it to smooth muscle relaxation, vasodilation, bronchodilation, immune signaling, circadian timing, and appetite control.

• VIP is a 28-amino-acid neuropeptide found in both the nervous system and peripheral tissues.
• It acts through two main receptors, VPAC1 and VPAC2, and has strong effects on blood vessels, airways, and immune cells.
• Animal and human research connects VIP with inflammation control, circadian rhythms, breathing, and feeding behavior.
• Recent research also points to context-specific effects in cancer, including a 2026 report on VIP-induced mitochondrial fragmentation in nasopharyngeal carcinoma.

What VIP is

VIP is a naturally occurring signaling molecule. One review describes it as a major immunoregulatory neuropeptide that is widely distributed in the central and peripheral nervous systems. It is also made by immune cells, not just neurons. VIP signals through the G-protein-coupled receptors VPAC1 and VPAC2, which are found in tissues such as the hypothalamus, lung, small intestine, immune cells, pituitary gland, and vascular smooth muscle.

That receptor pattern helps explain why VIP has effects in many systems at once. It can relax smooth muscle, suppress some inflammatory signals, support regulatory immune responses, and influence circadian biology. A lab reference also describes VIP as a pleiotropic regulatory molecule with anti-inflammatory, bronchodilatory, neuroprotective, chronobiotic, and immunomodulatory functions.

Where it shows up

VIP has been reported in the enteric nervous system, the central nervous system, the peripheral nervous system, and the lungs. A review of appetite and body composition used VIP-deficient mice and highlights how broad the peptide’s biology is. Other summaries note that VIP is also present in the brain, heart, pancreas, and immune cells.

In practical terms, this means VIP is not a single-purpose signal. It is a multi-system regulator.

How VIP works in the body

VIP acts through VPAC1 and VPAC2 receptors. These receptors are described in the research as being present on many cell types, including immune cells and vascular smooth muscle. When VIP binds these receptors, it can change how cells release inflammatory signals, handle smooth muscle tone, and respond to other nearby cues.

Blood vessels and airways

VIP was originally named for its strong vasodilatory effects in the gut. Later work expanded that view. A research summary describes VIP as the primary endogenous bronchodilator and pulmonary vasodilator in the lungs. In that setting, it is produced by non-adrenergic non-cholinergic neurons.

Because of those actions, VIP has been discussed in relation to airway tone and vascular regulation. A lab reference also notes that VIP-deficient states are associated with pulmonary arterial hypertension and airway hyperresponsiveness.

Immune signaling

One of the most consistent themes in VIP research is immune modulation. The 2015 review in PMC describes VIP as a major immunoregulatory neuropeptide. It notes that VIP and its receptors are involved in immune deviation, control of acute inflammation, and the regulation of inflammatory and autoimmune disorders.

The same review explains that VIP can shape the balance between inflammatory and regulatory immune responses. It is linked with tolerogenic dendritic cells, T cell differentiation, and broader anti-inflammatory signaling. Another source states that VIP suppresses NF-kB activation and downstream cytokines such as IL-6, TNF-alpha, IL-12, and MMP-9 while promoting IL-10 and TGF-beta1-related signaling. Those are specific pathways that help explain why VIP has been studied in inflammatory settings.

What the research says about inflammation

VIP is often discussed as an anti-inflammatory peptide, but the research is more precise than that label. It is better understood as a regulator of immune tone. Depending on the tissue and context, it may quiet some inflammatory pathways while supporting protective or repair-oriented responses.

The 2015 review emphasizes VIP’s role in immune privileged organs such as the central nervous system. It describes how the brain and other protected tissues rely on anti-inflammatory mechanisms to avoid damage from overactive immune responses. In that setting, VIP is part of a larger network that includes regulatory T cells, tolerogenic dendritic cells, and anti-inflammatory mediators.

Another source highlights VIP’s links to inflammatory and autoimmune disorders and presents both endogenous and exogenous VIP as research topics in those conditions. That does not mean VIP is a general treatment for inflammation. It means researchers continue to study how it affects immune balance in specific disease models.

Why context matters

VIP does not act the same way in every tissue. In immune cells, it may reduce pro-inflammatory signaling. In tumors, it may behave differently. In the lungs, it can relax airway smooth muscle. In the brain, it may help regulate timing signals and sleep-wake patterns. The best way to read the literature is as a set of tissue-specific effects, not as one simple action.

VIP in breathing, sleep, and appetite

VIP appears in systems that control breathing, daily rhythms, and feeding behavior. These roles are part of why it attracts interest across many fields, from pulmonary medicine to neuroscience.

Respiratory research

A 2010 phase two trial in 20 patients with sarcoidosis is cited in the provided material as showing that nebulized VIP significantly reduced pulmonary TNF-alpha, a key inflammatory marker. That is a concrete human data point often used to support continued interest in VIP in respiratory research.

Other summaries describe VIP as the primary endogenous bronchodilator in the lungs. That makes respiratory research a natural area of focus, especially where airway tone and inflammation overlap.

Circadian rhythm and sleep-wake timing

VIP is also linked with the suprachiasmatic nucleus, the brain’s central clock. A lab reference states that VIP produced by SCN neurons helps regulate circadian rhythm entrainment and is required for normal sleep-wake cycle maintenance. Another source describes VIP as affecting brain blood flow, melatonin, and circadian rhythm, and notes that its levels may be highest in the morning.

This is one reason VIP is often described as chronobiotic. It does not merely act on the body in general. It appears tied to timing systems that organize daily physiology.

Feeding and body composition

Animal research also points to a role in appetite and metabolism. A study using VIP-deficient mice examined body composition and feeding behavior over time. The fact that these experiments were done at all shows that VIP is considered relevant to feeding control and energy balance.

The broader interpretation is simple: VIP is not only a nerve signal or only an immune signal. It also participates in how the body manages intake, timing, and tissue-level coordination.

VIP and cancer research

VIP is not only studied for protective or regulatory roles. It also appears in cancer research, where its effects can depend on the tumor type and cellular context.

A 2026 PubMed entry reports that the PKCδ-Drp1 axis mediates VIP-induced mitochondrial fragmentation and metabolic crisis in nasopharyngeal carcinoma. That is a specific mechanistic finding. It suggests that VIP can trigger harmful metabolic stress in at least one cancer context rather than acting as a simple protective factor.

An older AACR entry in the provided material also points to VIP stimulating in vitro growth. Even without the full paper details here, the title alone is a reminder that VIP’s biology is not uniformly beneficial or suppressive across all systems. In cancer research, the direction of effect depends on the model, receptor profile, and downstream pathways involved.

What this means for interpretation

VIP should be treated as a context-dependent signaling molecule. In one setting, it may lower inflammatory tone. In another, it may support tumor-related processes. That is why clean mechanistic work matters so much in this field.

What clinicians and researchers usually watch

Across the provided sources, VIP comes up in connection with inflammation, respiratory function, circadian timing, and immune regulation. A compounding-focused guide also notes that intranasal VIP has been explored in contexts involving inflammation and immune regulation, though the source is educational and not a substitute for medical advice. It lists example dosing ranges used in some protocols, such as 0.2 to 0.4 mg daily for inflammatory support, up to 0.4 mg daily for respiratory protocols, and 0.2 mg daily as a starting point for neurological uses.

Those figures are presented as protocol examples, not universal standards. They should not be treated as general recommendations. The same guide also describes possible side effects such as nasal discomfort, headache, flushing, mild dizziness, stomach upset, transient blood pressure changes, allergic reactions, and respiratory irritation.

Because VIP affects vascular tone and immune pathways, any real-world use needs careful medical oversight. The provided material also flags cautions around uncontrolled hypertension, pregnancy, and possible interactions with vasodilators.

How to read the VIP literature

The strongest lesson from the research is that VIP is a broad regulator with tissue-specific actions. It is not a simple on-off switch. It is a signal that can change direction depending on where it acts and which receptors are present.

Here is a practical way to think about the literature:

If you are looking at immune biology, focus on VIP’s effects on cytokines, dendritic cells, T cells, and inflammatory signaling.

If you are looking at lung biology, focus on bronchodilation, pulmonary vasodilation, and airway hyperresponsiveness.

If you are looking at neuroscience, focus on circadian entrainment, sleep-wake timing, and neuroprotective roles.

If you are looking at oncology, focus on model-specific receptor signaling and downstream metabolic effects.

That framework helps keep claims grounded. VIP is interesting precisely because it crosses so many systems, but each claim still needs a specific context.

FAQ

What is VIP?

VIP is vasoactive intestinal peptide, a 28-amino-acid neuropeptide found in the nervous system, gut, lungs, and immune cells. It signals through VPAC1 and VPAC2 receptors.

What does VIP do?

Research links VIP to vasodilation, bronchodilation, immune regulation, circadian rhythm control, and effects on feeding behavior. Its role depends on the tissue and disease context.

Is VIP only a gut peptide?

No. Although it was first named for effects in the gut, the research shows that VIP is widely distributed in the brain, lungs, peripheral nerves, and immune system.

Why is VIP studied in inflammation?

VIP can suppress some inflammatory pathways and support regulatory immune signaling. Reviews describe it as important in inflammatory and autoimmune disorders and in immune-privileged tissues.

Does VIP always have the same effect?

No. VIP is context-dependent. It may reduce inflammation in one setting, help regulate breathing in another, and show different effects in cancer models such as nasopharyngeal carcinoma.